Tuesday, August 20, 2019 9:22:58 AM
MarketWatch
Tomi Kilgore
MarketWatchAugust 20, 2019
Shares of Nabriva Therapeutics PLC shot up 27% to pace the premarket gainers in active trading Tuesday, after the biotechnology company said its new drug application (NDA) for the oral and intravenous formulations of Xenleta, a treatment for community-acquired bacteria pneumonia, was approved by the Food and Drug Administration. Trading volume of over 1.3 million shares was already more than the full-day average of about 922,000 shares. "Today's approval of XENLETA is a significant breakthrough in the collective fight against the growing threat of antimicrobial resistance and provides a desperately needed IV and oral empiric monotherapy treatment option for adults with CABP," said Chief Executive Ted Schroeder. The company expects Xenleta to be available in mid-September through U.S. specialty distributors, and will have a wholesale acquisition price of $205 per IV patient treatment day and $275 per oral patient treatment day. The stock has slumped 7.5% over the past three months through Monday, while the S&P 500 has gained 2.9%.
https://finance.yahoo.com/m/030eca16-3952-3a54-8d2d-20c7f3467fe7/nabriva-therapeutics%26%2339%3B.html
Recent NBRVF News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:08:06 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM